LONDON, January 16, 2015 /PRNewswire/ --
Investor-Edge has initiated coverage on the following equities: Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Allergan Inc. (NYSE: AGN), Endo International PLC (NASDAQ: ENDP), Akorn Inc. (NASDAQ: AKRX), and Depomed Inc. (NASDAQ: DEPO). Free research reports can be accessed at: http://investor-edge.com/register. On Thursday, January 15, 2015, the NASDAQ Composite ended at 4,570.82, down 1.48%, the Dow Jones Industrial Average declined 0.61%, to finish the day at 17,320.71, and the S&P 500 closed at 1,992.67, down 0.92%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.29, down 1.07%, while the index has advanced 14.16% in the previous three months. Register for your complimentary reports at:
Teva Pharmaceutical Industries Ltd's stock finished Thursday's session 0.86% higher at $57.19. A total of 4.55 million shares were traded, which was above its three months average volume of 4.09 million shares. The stock moved between $57.11 and $57.95 during the session. Over the last one month and the previous three months, Teva Pharmaceutical Industries Ltd's shares have advanced 2.82% and 14.17%, respectively. Additionally, the stock has surged 29.95% in the past one year. The company's shares closed above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $57.06 is greater than its 200-day moving average of $53.42. Teva Pharmaceutical Industries Ltd's stock has a Relative Strength Index (RSI) of 49.86. Sign up and read the free notes on TEVA at:
On Thursday, shares in Allergan Inc. fluctuated between $215.57 and $217.67 before ending the session 0.57% lower at $215.70. The stock reported a trading volume of 1.28 million shares, much below its three months average volume of 3.00 million shares. Shares of the company traded at a PE ratio of 40.36. Allergan Inc.'s shares have advanced 3.20% in the last one month, 21.46% in the previous three months and 76.95% in the last one year. The company's stock closed above its 50-day and 200-day moving averages of $208.93 and $175.55, respectively. Moreover, shares of Allergan Inc. have an RSI of 59.53. The complimentary notes on AGN can be downloaded as in PDF format at:
Endo International PLC's stock lost 1.28%, to close the day at $78.08. The stock recorded a trading volume of 1.69 million shares, below its three months average volume of 1.95 million shares. The stock oscillated between $77.92 and $79.72 during the session. Over the last one month and over the past three months, Endo International PLC's shares have gained 16.07% and 29.72%, respectively. Further, the stock has gained 10.00% in the previous year. The company's stock closed above its 50-day and 200-day moving averages. The stock's 50-day moving average of $71.46 is above its 200-day moving average of $67.50. Additionally, Endo International PLC has an RSI of 70.26. Register for free on Investor-Edge and access the latest research on ENDP at:
On Thursday, shares in Akorn Inc. recorded a trading volume of 1.44 million shares, close to its three months average volume of 1.46 million shares. The stock ended the day at $40.46, which was 3.07% below its previous day's closing of $41.74, and registered an intraday range of $40.28 and $42.49. Shares of the company traded at a PE ratio of 140.34. Akorn Inc.'s shares have gained 1.86% in the last one month, 15.77% in the previous three months and 76.68% in the past one year. The company's stock closed above its 50-day and 200-day moving averages of $38.59 and $33.84, respectively. Furthermore, shares of Akorn Inc. have an RSI of 65.00. The complete research on AKRX is available for free at:
Depomed Inc.'s stock declined 2.22%, to close Thursday's session at $17.65, after oscillating between $17.58 and $18.23. The stock recorded a trading volume of 0.66 million shares, below its three months average volume of 0.80 million shares. Over the last one month and previous three months, Depomed Inc.'s shares have surged 19.90% and 23.43%, respectively. Additionally, the stock has gained 47.58% in the last one year. The company's stock closed above its 50-day and 200-day moving averages. The stock's 50-day moving average of $15.69 is above its 200-day moving average of $13.96. Further, Depomed Inc.'s stock traded at a PE ratio of 13.11 and has an RSI of 72.79. Free in depth research on DEPO is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.